Navigation Links
MiddleBrook Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
Date:3/14/2008

Presentation will be webcast live and archived on Company's web site

GERMANTOWN, Md., March 14 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that Dr. Edward M. Rudnic, MiddleBrook president and CEO, will deliver a corporate presentation on Tuesday, March 18, 2008, at 4:45 p.m. Eastern Time.

The presentation will take place as part of the Lehman Brothers Eleventh Annual Global Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida. Dr. Rudnic's remarks will be available live on the MiddleBrook web site, where they also will be archived for 30 days.

To access the presentation, log on to http://www.middlebrookpharma.com and click on the Presentations option in the Investor Relations section. Please connect to the web site several minutes prior to the start of the live presentation to ensure adequate time for any software download that may be necessary.

About MiddleBrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on the development and commercialization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front- loaded staccato bursts, or "pulses," are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(TM). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more on MiddleBrook, please visit http://www.middlebrookpharma.com.


'/>"/>
SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
11. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)...  Personal Genome Diagnostics Inc. (PGDx) today announced ... the U.S. Department of Veterans Affairs (VA) that ... company,s new CancerSELECT ™ 125 test. CancerSELECT ... test that includes microsatellite instability status (MSI), a ... checkpoint inhibitor immunotherapies. CancerSELECT 125 will be available ...
(Date:3/20/2017)... CA (PRWEB) , ... March ... ... are substances that interfere with the ability of endogenous hormones to regulate ... inhibiting ligand binding activity (antagonists), EDCs produce adverse reproductive, neurological, proliferative, and ...
(Date:3/20/2017)... ... March 20, 2017 , ... Charm Sciences, ... & play system that counts Peel Plate microbial test colonies, stores plate images, ... stand-alone unit has an internal computer, and is accurate within 10% of an ...
(Date:3/20/2017)... , March 20, 2017 Western Institutional Review ... ethical review of clinical research, announced today the launch ... (SRS) for NIH-funded multi-site research. As the ... institution clients, WIRB has an extensive background in reviewing ... status as the IRB of record for the majority ...
Breaking Biology Technology:
(Date:2/26/2017)...  Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring, announces the appointment of ... "Too often, too many offenders return to jail ... trying to tackle this ongoing problem and improve ... members. While significant steps are underway, Securus continues to ...
(Date:2/22/2017)... 22, 2017 With the biometrics market ... identifies four technologies that innovative and agile startups ... share in the changing competitive landscape: multifactor authentication ...   "Companies can no longer afford ... says Dimitrios Pavlakis , Industry Analyst at ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
Breaking Biology News(10 mins):